Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the antitumor efficacy of crenolanib (CP-868,596) in
patients with recurrent high grade glioma and in patients with low grade glioma.